dermatology advances

Brodalumab approved for psoriasisDr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
Center’s goal: Give skin disease researchers all they needA new research center makes a database of five million human pathology specimens and 22,000 living consented patients, all searchable by diagnoses, as well as cutting edge human analytic techniques available to anyone interested in carrying out translational skin disease research on human cells and tissues.
Literature updates in pediatric dermatologyA recent pediatric allergy study spells out how to safely introduce peanuts to high-risk (and other) children. Another study suggests that melatonin may have immunomodulatory effects in AD.
Study: Compound found in vegetables could have anti-aging effectsA recent study found that the compound, NMN, boosts production of NAD+ in mice and could have anti-aging effects along with additional benefits, but more research is necessary to determine its effect on humans.
Research looks at melanocyte role in tumor formationWhile melanocytes have strong mechanisms for repair, those in individuals with certain risk factors may carry impaired repair responses. Studies have begun to examine melanocytes in patients at risk for developing melanoma with the hope of developing strategies for preventing deadly tumors.
New target could predict melanomaNew information could eventually help identify a high-risk population before they get cancer — even prevent skin cancer’s onset.
The oral pipeline for psoriasisOral options in the pipeline for psoriasis show promise.
Combination therapy shows promising phase 2 resultsData suggest photodynamic therapy with the investigational topical methyl aminolevulinate may be an effective treatment for patients with severe facial acne.
Studies you may have missedOne expert summarizes science outside of dermatology that offers insight into the genetic toll of sun damage, the potential skin-protecting effects of vitamin B3, the sun-exposure threat posed by automobile side windows and more.
Ixekizumab effective psoriasis treatment through 60 weeksResults from three phase 3 trials, suggest ixekizumab (Talz, Eli Lilly & Company) is effective through 60 weeks of treatment among patients with moderate-to-severe plaque psoriasis.